HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

Acquired resistance to platinum (Pt)‐based therapies is an urgent unmet need in the management of epithelial ovarian cancer (EOC) patients. Here, we characterized by an unbiased proteomics method three isogenic EOC models of acquired Pt resistance (TOV‐112D, OVSAHO, and MDAH‐2774). Using this approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Rita, Sonego, Maura, Pucci, Biagio, Addi, Laura, Iannelli, Federica, Capone, Francesca, Alfano, Luigi, Roca, Maria Serena, Milone, Maria Rita, Moccia, Tania, Costa, Alice, Di Gennaro, Elena, Bruzzese, Francesca, Baldassarre, Gustavo, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024727/
https://www.ncbi.nlm.nih.gov/pubmed/33331136
http://dx.doi.org/10.1002/1878-0261.12883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024727/
https://www.ncbi.nlm.nih.gov/pubmed/33331136
http://dx.doi.org/10.1002/1878-0261.12883

Ejemplares similares